Journal
NATURE MEDICINE
Volume 6, Issue 6, Pages 703-706Publisher
NATURE AMERICA INC
DOI: 10.1038/76287
Keywords
-
Ask authors/readers for more resources
The androgen receptor (AR) is involved in the development, growth and progression of prostate cancer(1) (CaP). CaP often progresses from an androgen-dependent to an androgen-independent tumor, making androgen ablation therapy ineffective. However, the mechanisms for the development of androgen-independent CaP are unclear. More than 80% of clinically androgen-independent prostate tumors show high levels of AR expression(1). In some CaPs, AR levels are increased because of gene amplification(2) and/or overexpression, whereas in others, the AR is mutated(3-5). Nonetheless, the involvement of the AR in the transition of CaP to androgen-independent growth and the subsequent failure of endocrine therapy are not fully understood. Here we show that in CaP cells from a patient who failed androgen ablation therapy, a doubly mutated AR functioned as a high-affinity cortisol/cortisone receptor (AR(ccr)). Cortisol, the main circulating glucocorticoid, and its metabolite, cortisone, both equally stimulate the growth of these CaP cells and increase the secretion of prostate-specific antigen in the absence of androgens. The physiological concentrations of free cortisol and total cortisone in men(6,7) greatly exceed the binding affinity of the androgen and cortisol/cortisone receptor (AR(ccr)) and would activate the receptor, promoting CaP cell proliferation. Our data demonstrate a previously unknown mechanism for the androgen-independent growth of advanced CaP. Understanding this mechanism and recognizing the presence of glucocorticoid-responsive AR mutants are important for the development of new forms of therapy for the treatment of this subset of CaP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available